Últimas noticias sobre Exela Technologies (OTC:XELA) Bolsa

Exela Technologies

Exela Technologies Inc is a business process automation (BPA) leader combining industry-specific and multi-industry enterprise software and solutions. The company's BPA suite of solutions is deployed in banking, healthcare, insurance, and other industries. The company's segment includes Information and Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal and Loss Prevention Services (LLPS). It generates maximum revenue from the ITPS segment.

EXELA TECHNOLOGIES INC by Exela Technologies, Inc.

Exela Technologies Inc

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $154 to $137.

News

Price Target

Analyst Ratings

NBIX

UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $137

Trading Ideas

AREB

American Rebel Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Up 143.4%

TD Securities analyst Max Rakhlenko initiates coverage on Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) with a Buy rating and announces Price Target of $40.

Initiation

TD Securities Initiates Coverage On Valvoline with Buy Rating, Announces Price Target of $40

Offerings

AIM ImmunoTech Enters $3M Equity Distribution Agreement With Maxim Group For "At the Market" Offering

Citigroup analyst Ygal Arounian downgrades Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Buy to Neutral and lowers the price target from $58 to $28.

Downgrades

Citigroup Downgrades Wayfair to Neutral, Lowers Price Target to $28

Guggenheim analyst Michael Schmidt maintains Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) with a Buy and lowers the price target from $12 to $8.

NBTX

Guggenheim Maintains Buy on Nanobiotix, Lowers Price Target to $8

Truist Securities analyst John McDonald maintains PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) with a Hold and lowers the price target from $216 to $208.

Truist Securities Maintains Hold on PNC Financial Services Gr, Lowers Price Target to $208

Guggenheim analyst Gregory Francfort maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Buy and raises the price target from $71 to $77.

Guggenheim Maintains Buy on Restaurant Brands Intl, Raises Price Target to $77

The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">G4-related disease (IgG4-RD)</a>.
IgG4-RD is a&nbsp;chronic immune-mediated fibroinflammatory disorder that often manifests with tumor-like masses and/or painless <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44634869/uplizna-inebilizumab-cdon-is-now-the-first-and-only-fda-approved-treatment-for-igg4-related-diseas" rel="noreferrer noopener">enlargement of multiple organs</a>.&nbsp;
This is the second approved indication for Uplizna, which the FDA previously approved for adult patients with AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder (NMOSD) in&nbsp;June 2020.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44307450/amgens-uplizna-shows-improved-symptoms-in-patients-with-muscle-weakness-disorder-over-one-year" rel="noreferrer noopener">Amgen&#8217;s Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year</a>
The FDA also granted Uplizna Orphan Drug Designation for generalized myasthenia gravis (gMG). Regulatory filing activities are underway for gMG, and submission is anticipated to be completed in H1 2025.
The approval is supported by data from the MITIGATE trial. The trial demonstrated the potential of Uplizna to decrease disease activity by reducing flares in patients while maintaining its efficacy and established safety profile.
Key findings from the MITIGATE trial include:
<ul>
<li>There was an 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period; 10.3% of participants receiving Uplizna experienced a flare compared to 59.7% of participants receiving placebo.</li>
<li>57.4% of participants receiving Uplizna achieved flare-free, treatment-free, and complete remission at Week 52 compared to 22.4% on placebo.</li>
<li>58.8% of participants receiving Uplizna achieved flare-free, corticosteroid-free, and complete remission at Week 52 compared to 22.4% on placebo.</li>
</ul>
<h2 class="wp-block-heading">Amgen Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Amgen, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Amgen, the 200-day moving average sits at $306.84, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $309.85. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: AMGN stock is down 1.05% at $306.59 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44644795/brookfield-strikes-9-billion-deal-for-colonial-pipeline-shell-offloads-minority-stake" target="_blank" rel="noreferrer noopener">Brookfield Strikes $9 Billion Deal For Colonial Pipeline—Shell Offloads Minority Stake</a></li>
</ul>
Photo: Shutterstock/JHVEPhoto

Biotech

Large Cap

Health Care

General

AMGN

FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 5 years by 2.14% on an annualized basis producing an average annual return of 16.48%. Currently, Jones Lang LaSalle has a market capitalization of $10.99 billion. 
Buying $1000 In JLL: If an investor had bought $1000 of JLL stock 5 years ago, it would be worth $2,340.57 today based on a price of $232.00 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743777011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

BWS Financial analyst Hamed Khorsand maintains Garrett Motion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) with a Buy and maintains $12 price target.

BWS Financial Maintains Buy on Garrett Motion, Maintains $12 Price Target

Guggenheim analyst Etzer Darout maintains Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) with a Buy and lowers the price target from $12 to $9.

Guggenheim Maintains Buy on Inventiva, Lowers Price Target to $9

Truist Securities analyst John McDonald maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold and lowers the price target from $268 to $264.

Truist Securities Maintains Hold on JPMorgan Chase, Lowers Price Target to $264

Truist Securities analyst John McDonald maintains Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) with a Buy and lowers the price target from $85 to $84.

Truist Securities Maintains Buy on Citigroup, Lowers Price Target to $84

Truist Securities analyst John McDonald maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Buy and lowers the price target from $53 to $50.

Truist Securities Maintains Buy on Bank of America, Lowers Price Target to $50

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is holding strong despite traditional financial markets trending down, though not all traders are convinced <a href="https://www.benzinga.com/money/bitcoin-price-prediction">this strength will persist</a>.
What Happened: Crypto Bully <a href="https://x.com/BullyDCrypto/status/1908130932239831118">notes</a> Bitcoin has traded in the same range for over three weeks, offering profitable short-term plays. 
Despite no major long liquidations at range lows, persistent spot selling suggests a potential breakdown may be on the table.
Crypto trader Niels <a href="https://x.com/Web3Niels/status/1908084954170323308">highlights</a> that while the NASDAQ plunged 5.5% in a day, the worst performance since 2020 and erasing $2.85 trillion in value, Bitcoin closed the day up.
He says due to the highly volatile and liquid nature of Bitcoin, it tends to bottom before traditional markets, a trend he sees playing out again.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44634188/are-bitcoin-and-the-sp-500-heading-for-a-death-cross">Are Bitcoin And The S&amp;P 500 Heading For A Death Cross?</a>
What's Next: More Crypto Online <a href="https://x.com/Morecryptoonl/status/1908076675511787696">points</a> to BTC bouncing off key $79,000–$81,000 support, aligning with a technical corrective move. 
The critical resistance to break is between $84,860 and $86,960—if BTC clears this zone, bulls could target the mid-$90,000s. 
On the downside, support at $81,250 needs to hold, losing it could send BTC down to $75,000. 
The trader predicts today's price reaction will be pivotal in determining whether this is a breakout or a fakeout.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44630045/99-of-americans-know-bitcoin-but-only-91-know-dogecoin-why">99% Of Americans Know Bitcoin, But Only 91% Know Dogecoin: Why?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Holds The Line At $82,000: What Traders See Happening Next

Citizens Capital Markets analyst David Scharf reinstates Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) with a Market Perform.

LPRO

Citizens Capital Markets Reinstates Market Perform on Open Lending

Truist Securities analyst Bill Chappell initiates coverage on Primo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>) with a Buy rating and announces Price Target of $42.

PRMB

Truist Securities Initiates Coverage On Primo Brands with Buy Rating, Announces Price Target of $42

Citigroup analyst Scott Gruber maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Buy and lowers the price target from $46 to $43.

Citigroup Maintains Buy on Devon Energy, Lowers Price Target to $43

<ul>
<li>Hooters announced Monday it filed for Chapter 11 bankruptcy protection </li>
<li>The company plans to sell its 100 owned locations to two franchise groups</li>
<li>Hooters has said it will take 90-120 days to exit bankruptcy</li>
</ul>
Hooters, the restaurant chain known for its all-female waitstaff, neon orange branding, and chicken wings, on Monday it filed for bankruptcy protection.&nbsp;
Hooters of America said the Chapter 11 bankruptcy filing would allow it to continue normal operations during the proceeding.&nbsp;&nbsp;
Hooters said in a <a href="https://www.hooters.com/about/news/hooters-of-america-takes-strategic-action-to-continue-its-iconic-legacy">statement</a> that all of the 100 restaurants it currently owns will be sold off to two existing franchisees. The existing franchisees own and operate more than 30% of Hooters locations in the U.S. .
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a></li>
</ul>
One of the franchisees is Hooters Inc., which includes many of the original Hooters founders.
"With over 30 years of hands-on experience across the Hooters ecosystem, we have a profound understanding of our customers and what it takes to not only meet, but consistently exceed their expectations," Hooters Inc. CEO Neil Kiefer, speaking on behalf of the buying groups, said in the statement. "As we look toward the future, we are committed to restoring the Hooters brand back to its roots and simplifying [Hooter's of America's] operations by adopting a pure franchise model that will maximize the potential for sustainable, long-term growth."
The bankruptcy filing was made in the U.S. Bankruptcy Court for the Northern District of Texas. Hooters is seeking approval of $40 million of debtor-in-possession financing from its existing lenders, including $35 million of new capital. As of this writing, it has acquired just $35 million from its existing lender group to help complete the bankruptcy transaction. The company expects to exit the proceedings in 90-120 days.&nbsp;
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
"Our renowned Hooters restaurants are here to stay," Hooters of America CEO Sal Melilli said in the statement. "Today's announcement marks an important milestone in our efforts to reinforce Hooters' financial foundation and continue delivering the guest-obsessed hospitality experience and delicious food our customers and communities have come to expect. I've seen firsthand the incredible value and opportunities our brand brings to life, and I look forward to continuing that momentum well into the future."&nbsp;
The iconic owl logo and flavorful wings might be here to stay, but the company's image will likely be receiving quite a facelift. In an interview last week with <a href="https://www.bloomberg.com/news/features/2025-03-27/hooters-bankruptcy-founders-to-welcome-families-end-bikini-nights">Bloomberg</a>, Kiefer teased plans to make the restaurant chain more family friendly. The first things on the chopping block for the CEO are the iconic uniforms and gimmicks like Bikini Day.&nbsp;
Hooters, which is owned by private-equity firms Nord Bay Capital and TriArtisan Capital Advisors, first <a href="https://www.benzinga.com/news/asset-sales/25/02/43897289/deal-dispatch-hooters-plans-restructuring-prada-in-talks-to-acquire-versace">revealed plans</a> for a potential restructuring in February.&nbsp;
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Comments

Exela Technologies

Noticias

Últimas noticias sobre Exela Technologies (OTC:XELA) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL